BML Capital Management’s Adicet Bio ACET Stock Holding History

BML Capital Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,875	Closed	-$173K	–	32
2023 Q1	$173K	Hold	1,875	–	–	0.15%	30
2022 Q4	$268K	Buy	+1,875	New	+$468K	0.26%	23

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BML Capital Management's ACET Position: Q2 2023 in Review

BML Capital Management sold out of Adicet Bio (ACET) in Q2 2023, closing a stake of 1,875 shares — an estimated $173K sold.

BML Capital Management first reported a position in ACET in Q4 2022 and held it in 2 quarters. The position peaked at $268K in Q4 2022. 94 funds tracked by Wall St. Rank hold ACET as of Q2 2023.

BML Capital Management reported no remaining Adicet Bio position as of Q2 2023 after selling out during the quarter.
BML Capital Management sold 1,875 Adicet Bio shares in Q2 2023, an estimated $173K.
BML Capital Management first reported a position in Adicet Bio in Q4 2022 and held it in 2 quarters.
BML Capital Management's Adicet Bio position peaked at $268K in Q4 2022.
94 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2023.

Based on BML Capital Management's 13F filing for Q2 2023, filed 24 Jul 2023.